Presidio Pharmaceuticals  
Presidio是一家位于旧金山的制药公司，其专业领域是发现和开发泛基因型HCV口服治疗药物。目前，公司正致力于开发针对HCV NS5A 和NS5B基因的新型抑制剂。 PPI-668是在研的、泛基因型、每日给药一次的NS5A抑制剂。在健康志愿者以及HCV感染者中开展的早期临床研究结果显示，到目前为止，观察到PPI-668具有良好的耐受性，未发生严重或重度不良事件，而且未观察到明显的与治疗有关的临床副反应或实验室检查异常。 PPI-668所达到的血药浓度足以抑制大多数之前存在耐药变异的病毒，而且单剂给药就可达到稳态水平。在一项针对PPI-668单药治疗应用于 GT1 HCV感染者的临床试验中，在治疗1至2天后的病毒载量降幅达到了3.5—3.7 log10 HCV。该药应用于GT3 HCV感染者的有效性也已被证实。

Presidio公司的NS5B抑制剂PPI-383是一种新型、泛基因型、非核苷类抑制剂，该药具有抑制所有主要的HCV基因型的潜力。这一化合物目前正处于针对健康受试者的I期临床试验中。

Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s current focus is on effective therapies for hepatitis C virus (HCV) infection. With a current pipeline consisting of compounds targeting both the NS5A and NS5B proteins of HCV, Presidio is well positioned to compete in the growing HCV therapy market (see Programs & Pipeline for more details). Presidio’s goal is to discover and advance small-molecule, antiviral drug candidates that are potent, have pan-genotypic antiviral activity, offer convenient once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance. The best future combination regimens will require such characteristics, to simplify patient treatment and to ensure that drug therapy will be effective against the wide variety of known HCV genotypes.